Early safety check: how a new cancer drug interacts with common meds
NCT ID NCT05509816
Summary
This early-stage study aimed to understand how a new breast cancer drug, imlunestrant, might affect how the body processes other medications. It involved 20 healthy women and measured how the drug changed levels of a common sedative in the blood. The main goal was to gather safety data on potential drug interactions before testing in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LabCorp CRU, Inc.
Daytona Beach, Florida, 32117, United States
-
LabCorp CRU, Inc.
Dallas, Texas, 75247, United States
Conditions
Explore the condition pages connected to this study.